ScienceOpen Author Interview Series – Nikos Karamanos

Today’s interview continues both the Author and the Editorial Board Interview Series with a conversation between ScienceOpen and Nikos Karamanos, Professor of Chemistry at the University of Patras in Greece. Professor Karamanos is one of the authors of the recent ScienceOpen publication, “EGF/EGFR signaling axis is a significant regulator of the proteasome expression and activity in colon cancer cells” ( ), and an established scholar, Editorial Board member for various journals, and chair and organizer of numerous conferences. He is principal investigator or Collaborator in National and (GSRT-PENED, THALIS, HRAKLEITOS, KESY, etc.), International (EU Leonardo, EU Comet, FEBS-ALC, FP7 etc.) and industrial research projects in the areas of biotechnology, oncology, safety analysis/cytotoxicology and pharmacokinetics and has authored hundreds of publications. He has received numerous awards from organizations such as the Society for Anticancer Research and the Federation of European Connective Tissue Societies.
We are delighted to have Professor Karamanos as both a charter member of our Editorial Board and one of our first authors at ScienceOpen. In today’s interview, we asked him about his current research, ScienceOpen as a platform for publication and Open Access publishing more generally.

Q. Congratulations on your new publication with ScienceOpen. Can you explain a little bit about the research itself and your work more generally?

A. Colon cancer is the third most common type of cancer. Our research is focused on identifying the roles of molecules implicated in the development and progression of the disease. In this study we evaluated the roles of two such molecules, known as cell receptors EGFR and IFGR, in the gene expression and activity of proteasome. Proteasome plays a crucial role in cancer, modulating growth and survival of cancer cells. Such data will help us to understand the mechanisms implicated and therefore to design and assist the development of novel pharmacological agents targeting this cancer type.

Q. What made you decide to publish this particular research with ScienceOpen and in an Open Access format?

A. ScienceOpen is a new and very promising publishing platform. It is a really fresh idea, quite contrary of the way we have published in the past. It is exciting to get your data published in a few days and to receive the ideas/comments and reviews at the same time, as well as to get input from experts in the area and to improve your research continuously.

Q. Tell us some of your thoughts on Open Access science publishing generally.

A. Open access in science is an opportunity for everyone to know about the new research findings and therefore for the scientists to obtain the highest possible visibility for their research. However, measures should be taken as to keep the publication costs as low as possible.

Q: Why did you decide to join the Editorial Board of ScienceOpen?

A. It is a unique, new style publishing platform that is promising and challenging.